CytomX Therapeutics

CTMXPhase 2

CytomX Therapeutics is developing a new class of targeted cancer therapies using its Probody platform, which aims to enhance the therapeutic window of antibody-based drugs by restricting their activity to diseased tissue. The company has advanced multiple candidates into clinical development, including its lead asset praluzatamab ravtansine (CX-2009), and has established high-value collaborations with industry leaders like AbbVie, Amgen, Astellas, and Bristol Myers Squibb. As a publicly traded company, CytomX is focused on leveraging its platform to address significant unmet needs in oncology while managing its capital to advance key programs.

Market Cap

$757.3M

Employees

100-150

Focus

Biotech

CTMX · Stock Price

USD 4.45+1.76 (+65.43%)

Historical price data

AI Company Overview

Technology Platform

Probody® technology platform, a proprietary approach to create conditionally activated antibody therapeutics that are designed to be activated specifically in the tumor microenvironment while remaining inactive in healthy tissue.

Pipeline Snapshot

8 drugs in pipeline

Drug	Indication	Stage
CX-2009 + CX-072	Neoplasms	Phase 2
CX-072 + Ipilimumab	Solid Tumor	Phase 2
CX-2029	Solid Tumor, Adult	Phase 1/2
CX-2009	Solid Tumor, Adult	Phase 1/2
CX-072 + ipilimumab + vemurafenib	Solid Tumor	Phase 1/2

Opportunities

The Probody platform offers the opportunity to target previously undruggable tumor antigens and improve the safety profile of potent immunotherapies like T-cell engagers and cytokines.

Successful clinical validation in ongoing partnered programs (e.g., CX-904 with Amgen) could unlock significant milestone payments and reignite platform value.

The internal next-generation immunocytokine pipeline represents a new, wholly-owned avenue for growth in the high-potential cytokine therapy space.

Risk Factors

High clinical development risk, as evidenced by the discontinuation of lead assets CX-2009 and CX-2029.

The company is heavily dependent on the success of partnered programs, which are outside its full control.

Despite a restructured cash runway, the pre-revenue company faces future dilution risk and intense competition from larger, well-funded oncology biopharma players.

Competitive Landscape

CytomX competes with major ADC developers (e.g., Daiichi Sankyo, AstraZeneca) and other conditional activation/platform companies like Zymeworks and Synaffix. Its key differentiation is the clinical-stage validation of its Probody platform across multiple therapeutic modalities (PDC, TCE, I-O) through strategic partnerships, though it must now prove clinical superiority to capture market share.

Publications

Patents

Pipeline